Compare AbCellera Biologics Inc (ABCL) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Target Corporation — how do they compare? AbCellera Biologics Inc trades at $9.94 (market cap $2.99B), while Target Corporation trades at $152.88 (market cap $69.17B). The key difference: Target Corporation is far larger — about 23.1× AbCellera Biologics Inc's market cap, and Target Corporation pays a 3.05% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | TGT | |
|---|---|---|
Market Cap | $2.99B | $69.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $152.35 |
52-Week Low | $2.78 | $83.68 |
Enterprise Value | $2.58B | $84.47B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
Target Corporation (TGT) trades at $152.85, up 0.5% today, near its 52-week high. The stock shows strong momentum with bullish technical signals and consistent earnings beats in recent quarters. Revenue remains stable around $106 billion, with a net income margin of 3.24% and solid cash flow from operations of $7.37 billion in 2025. Recent news includes the appointment of a chief AI officer, highlighting strategic focus on technology.
The outlook is positive with analyst consensus leaning buy, though valuation multiples like P/E of 20.12 suggest fair pricing. Risks include competitive retail pressures and macroeconomic sensitivity. Upside potential exists if AI initiatives drive efficiency, but investors should monitor Q2 2026 earnings for confirmation of growth trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
